Investors and the local healthcare industry want to make Philadelphia a rival to Silicon Valley in healthcare innovation, according to an article in Free Enterprise.
U.S. health insurers may be looking at some difficult decisions when it comes to whether they will cover an increasing array of genetic testing, according to a Kaiser Health News report.
Independence Blue Cross has become the first major insurer to cover next-generation whole genome sequencing for a variety of cancers.
In this exclusive FierceHealthcare special report, we explore some of the obstacles to innovation and how these unique ventures offer lasting lessons to healthcare leaders who want to drive change in the industry.
The best way to engage patients in their care is to take a personalized approach, leaders from Independence Blue Cross and Penn Medicine said during a recent panel at the BIO conference in Philadelphia.
For health plans, the case for robust analytics comes down to the numbers. Medication to treat hepatitis C costs $1,000 a dose, and patients who miss a dose need to start over, Dan Walczak, assistant director of healthcare informatics at Minnesota-based UCare, noted at the America's Health Insurance Plans AHIP Institute conference.
The ongoing shift in the way consumers interact with health insurance companies forces payers to treat them as members first and patients second.
Healthcare fraud, waste and abuse costs the United States as much as $270 billion annually. A Philadelphia-based startup called TrueClaim thinks it has found a solution to combat this spending issue by bringing patients into the claims reconciliation process.
Tandigm Health, the Philadelphia-area primary care venture started last year by Independence Blue Cross and Davita HealthCare Partners, has inked a deal with the Holy Redeemer Health System.
Philadelphia-based Independence Blue Cross has disclosed a data breach affecting roughly 12,500 members.